All analyses
AI analysis

Asiri Surgical Hospital PLC: research report

Fairly valuedbullishOct 16, 2026

Evidence points bullish because June profit grew 11.6% and borrowings have fallen. The catch is that operating cash conversion was only 0.33 times in the latest audited year.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June-quarter net profit rose 11.6% year-on-year as revenue increased 7.4%.
  • Debt fell to 24.2% of owners' equity at March 2026 from 37.1% a year earlier.
  • The share trades at 6.3 rupees for each rupee of trailing earnings, below the healthcare peer median of 11.9 times.

Against this. Operating cash flow was only 0.33 times operating profit in the latest audited year, so much of the reported operating profit had not arrived as cash.

Operating margin
18.1%
latest quarter
Net margin
15.4%sector 13.0%
from 12.1% a year earlier, revenue +17.6%
Return on equity
12.0%
twelve months to Sep 30, 2026, unaudited
P/E
7.0sector 11.8
earnings Rs 1.84 per share, year to Sep 2026
P/B
0.83sector 1.36
book Rs 15.34 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 16, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Surgical Hospital operates a private surgical hospital offering diagnostics, consultations, surgery and post-operative care across several specialist disciplines. The most important recent change is that revenue and profit continued to grow in the June quarter while gross profitability held firm, alongside a meaningful reduction in debt over the latest audited year.

Price performance

At LKR 10.10 on 15 October 2026, the share had fallen 31.8% over three months, versus a 6.8% fall in the ASPI. It sat 1.1% of the way up its 52-week range, placing the close near the period low; the data does not establish why the decline occurred.

The record shows four falls of 15% or more in three years, with the deepest 64% and not yet recovered. Median daily turnover was LKR 1.6 million, and a LKR 1 million order is about 62% of what trades on a typical day, a large part of a day's trading.

Valuation

At 6.3 times trailing earnings, the share represents 6.3 rupees paid for every rupee of the last twelve months' profit, against a healthcare peer median of 11.9 times. Its P/B is 0.72 times, meaning 72 cents paid for each rupee of net assets, versus a sector median of 1.92 times. A sector percentile is not available in the supplied anomalies data.

The share is cheaper than 94% of days since February 2012 on P/E and cheaper than 99% of days since February 2012 on P/B. Return on equity for the twelve months to June 2026 was 11.5%, so the low P/B is paired with a business that remained profitable rather than one reporting losses. No dividend is on record in the last two years. The latest quarter supplied 23.2% of trailing EPS, but its net margin was close to the year-ago level, leaving the present P/E unchanged on that margin comparison.

News and sentiment

Direct coverage is thin: there were three material articles over 90 days, split between one positive and two negative items. The available material item, reported on 17 August, concerned Softlogic Holdings and noted that a tax dispute involving Asiri Surgical Hospital remains under appeal; no financial exposure was disclosed in the supplied article.

Financials

June-quarter revenue rose 7.4% year-on-year to LKR 2.0 billion, while net profit increased 11.6% to LKR 226 million. That means profit grew faster than sales, adding to the earnings supporting the current valuation.

Gross margin was 43.2%, unchanged from 43.2% a year earlier, while net margin improved to 11.1% from 10.7%. Operating margin is unavailable for the June 2026 filing, so a like-for-like operating-margin comparison cannot be made. June gross margin was among the hospital's best June-quarter results, ranking second of six, while net margin ranked fourth of six, a more ordinary outcome.

The latest quarterly filing does not provide operating profit or the below-the-line bridge, so the source of the difference between operating and net profit cannot be separated. Equity was LKR 8.0 billion at June, and the share count was unchanged at 528.5 million. Part of group profit belongs to minority shareholders, so group net profit is not wholly the profit attributable to the ordinary shares being valued.

Risks

The main financial risk is weak cash realisation. In the year to March 2026, operating cash flow was 0.33 times operating profit: only about 33 cents of cash arrived for each rupee of operating profit, making the profit rise less reassuring than an equally profitable but cash-backed result.

Financing risk has improved but remains relevant. Gearing, meaning debt against owners' equity, fell to 24.2% from 37.1%, and interest cover improved to 4.78 times, meaning operating profit covered the interest bill nearly five times. The current ratio was 1.09 times, so current assets, including receivables and supplies, only narrowly exceeded bills due within a year. Minority shareholders received 13.4% of annual group profit, reducing the portion belonging to the shares under review.

Healthcare is the company's sole sector exposure. Government hospital-capacity plans reported in September deepen the state's role in healthcare provision, although the supplied data does not quantify any effect on Asiri Surgical Hospital.

Outlook

As at 16 October 2026, the next material company event is the interim filing for the quarter ended 30 September 2026, expected between 6 and 14 November. It will show whether the June revenue and profit growth continued and, if an operating-profit line is available, whether earnings growth is supported by operations rather than items below that line.

The data cannot establish the outcome of the pending tax appeal mentioned in the August article, nor quantify its potential effect on the hospital.

About this report. Generated on Oct 16, 2026 from market data up to Oct 15, 2026, 3 material news articles over 90 days and financials to Jun 30, 2026, and scored 63 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports